CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103568
035-os BibID:(Cikkazonosító)10061 (WOS)000852506000001 (Scopus)85137562418
Első szerző:Kálmán-Szabó Ibolya (molekuláris biológus)
Cím:PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer : comparative Preclinical Study of [68Ga]Ga-NODAGA-AMBA and [44Sc]Sc-NODAGA-AMBA / Ibolya Kálmán-Szabó, Judit P. Szabó, Viktória Arató, Noémi Dénes, Gábor Opposits, István Jószai, István Kertész, Zita Képes, Anikó Fekete, Dezső Szikra, István Hajdu, György Trencsényi
Dátum:2022
ISSN:1661-6596 1422-0067
Megjegyzések:Gastrin-releasing peptide receptors (GRPR) are overexpressed in prostate cancer (PCa). Since bombesin analogue aminobenzoic-acid (AMBA) binds to GRPR with high affinity, scandium-44 conjugated AMBA is a promising radiotracer in the PET diagnostics of GRPR positive tumors. Herein, the GRPR specificity of the newly synthetized [44Sc]Sc-NODAGA-AMBA was investigated in vitro and in vivo applying PCa PC-3 xenograft. After the in-vitro assessment of receptor binding, PC-3 tumor-bearing mice were injected with [44Sc]Sc/[68Ga]Ga-NODAGA-AMBA (in blocking studies with bombesin) and in-vivo PET examinations were performed to determine the radiotracer uptake in standardized uptake values (SUV). 44Sc/68Ga-labelled NODAGA-AMBA was produced with high molar activity (approx. 20 GBq/?moL) and excellent radiochemical purity. The in-vitro accumulation of [44Sc]Sc-NODAGA-AMBA in PC-3 cells was approximately 25-fold higher than that of the control HaCaT cells. Relatively higher uptake was found in vitro, ex vivo, and in vivo in the same tumor with the 44Sc-labelled probe compared to [68Ga]Ga-NODAGA-AMBA. The GRPR specificity of [44Sc]Sc-NODAGA-AMBA was confirmed by significantly (p ? 0.01) decreased %ID and SUV values in PC-3 tumors after bombesin pretreatment. The outstanding binding properties of the novel [44Sc]Sc-NODAGA-AMBA to GRPR outlines its potential to be a valuable radiotracer in the imaging of GRPR-positive PCa.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
[44Sc]Sc-NODAGA-AMBA
[68Ga]Ga-NODAGA-AMBA
gastrin-releasing peptide receptor (GRPR)
bombesin (BBN)
prostate cancer (PCa)
PC-3
positron emission tomography (PET)
Megjelenés:International Journal of Molecular Sciences. - 23 : 17 (2022), p. 1-17. -
További szerzők:Péli-Szabó Judit (1977-) (vegyész) Arató Viktória Zsófia (1989-) (gyógyszerész) Dénes Noémi (1992-) (vegyész) Opposits Gábor (1974-) (fizikus, szoftver fejlesztő) Jószai István (1978-) (vegyész) Kertész István (1966-) (vegyész) Képes Zita (1991-) (orvos) Fekete Anikó (1973-) (vegyész) Szikra Dezső Péter (1983-) (vegyész) Hajdu István (1981-) (vegyész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus)
Pályázati támogatás:EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
K119552
NKFIH
TKP2020-NKA-04
Egyéb
János Bolyai Research Scholarship of the Hungarian Academy of Sciences (bo_328_21)
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM110517
035-os BibID:(cikkazonosító)6942 (Scopus)85158060599 (WoS)000981008100001
Első szerző:Képes Zita (orvos)
Cím:Overview of Prostaglandin E2 (PGE2)-Targeting Radiolabelled Imaging Probes from Preclinical Perspective : Lessons Learned and Road Ahead / Képes Zita, Dénes Noémi, Kertész István, Hajdu István, Trencsényi György
Dátum:2023
ISSN:1422-0067
Megjegyzések:As malignancies still represent one of the major health concerns worldwide, early tumor identification is among the priorities of today's science. Given the strong association between cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2), PGE2 receptors (EPs), and carcinogenesis, target-specific molecules directed towards the components of the COX2/PGE2/EP axis seem to be promising imaging probes in the diagnostics of PGE2pos. neoplasms and in the design of anti-cancer drugs. Featured with outstanding inclusion forming capability, β-cyclodextrins (CDs) including randomly methylated β-CD (RAMEB) were reported to complex with PGE2. Therefore, radiolabelled β-CDs could be valuable vectors in the molecular imaging of PGE2-related tumorigenesis. In vivo preclinical small animal model systems applying positron emission tomography (PET) ensure a well-suited scenario for the assessment of PGE2-affine labelled CD derivatives. Previous translational studies dealt with the evaluation of the tumor-homing capability of Gallium-68 (68Ga) and Bismuth-205/206 (205/206Bi)-appended β-CD compounds conjugated with chelator NODAGA or DOTAGA: [68Ga]Ga-NODAGA-2-hydroxypropyl-β-cyclodextrin/HPBCD, [68Ga]Ga-NODAGARAMEB, [68Ga]Ga-DOTAGA-RAMEB, and [205/206Bi]Bi-DOTAGA-RAMEB in experimental tumors with different PGE2 expression. These imaging probes project the establishment of tailor-made PET diagnostics of PGE2pos. malignancies. In the present review, we provide a detailed overview of the in vivo investigations of radiolabelled PGE2-directed CDs, highlighting the importance of the integration of translational discoveries into routine clinical usage.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Bismuth-205/206 (205/206Bi)
cyclodextrins (CDs)
Gallium-68 (68Ga)
2-hydroxypropyl-β-cyclodextrin (HPBCD)
positron emission tomography (PET)
prostaglandin E2 (PGE2)
randomly methylated β-CD (RAMEB)
Megjelenés:International Journal Of Molecular Sciences. - 24 : 8 (2023), p. 1-15. -
További szerzők:Dénes Noémi (1992-) (vegyész) Kertész István (1966-) (vegyész) Hajdu István (1981-) (vegyész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus)
Pályázati támogatás:János Bolyai Research Scholarship of the Hungarian Academy of Sciences (bo_328_21)
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM105131
035-os BibID:(cikkazonosító)13950 (WOS)000887335500001 (Scopus)85142823505
Első szerző:Képes Zita (orvos)
Cím:In Vivo Preclinical Assessment of β-Amyloid-Affine [11C]C-PIB Accumulation in Aluminium-Induced Alzheimer's Disease-Resembling Hypercholesterinaemic Rat Model / Zita Képes, Alexandra Barkóczi, Judit P. Szabó, Ibolya Kálmán-Szabó, Viktória Arató, István Jószai, Ádám Deák, István Kertész, István Hajdu, György Trencsényi
Dátum:2022
ISSN:1422-0067
Megjegyzések:Aluminum (Al) excess and hypercholesterinaemia are established risks of Alzheimer's disease (AD). The aim of this study was to establish an AD-resembling hypercholesterinaemic animal model?with the involvement of 8 week and 48 week-old Fischer-344 rats?by Al administration for the safe and rapid verification of ? -amyloid-targeted positron emission tomography (PET) radiopharmaceuticals. Measurement of lipid parameters and ? -amyloid?affine [11C]C-Pittsburgh Compound B ([11C]C-PIB) PET examinations were performed. Compared with the control, the significantly elevated cholesterol and LDL levels of the rats receiving the cholesterol-rich diet support the development of hypercholesterinaemia (p?0.01). In the older cohort, a notably increased age-related radiopharmaceutical accumulation was registered compared to in the young (p?0.05; p?0.01). A monotherapy-induced slight elevation of mean standardised uptake values (SUVmean) was statistically not significant; however, adult rats administered a combined diet expressed remarkable SUVmean increment compared to the adult control (SUVmean: from 0.78?0.16 to 1.99?0.28). One and two months after restoration to normal diet, the cerebral [11C]C-PIB accumulation of AD-mimicking animals decreased by half and a third, respectively, to the baseline value. The proposed in vivo Al-induced AD-resembling animal system seems to be adequate for the understanding of AD neuropathology and future drug testing and radiopharmaceutical development.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:International Journal Of Molecular Sciences. - 23 (2022), p. 1-14. -
További szerzők:Barkóczi Alexandra Péli-Szabó Judit (1977-) (vegyész) Kálmán-Szabó Ibolya (1980-) (molekuláris biológus) Arató Viktória Zsófia (1989-) (gyógyszerész) Jószai István (1978-) (vegyész) Deák Ádám (1974-) (állatorvos) Kertész István (1966-) (vegyész) Hajdu István (1981-) (vegyész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM104375
035-os BibID:(cikkazonosító)13060 (WOS)000881332000001 (Scopus)85141644328
Első szerző:Képes Zita (orvos)
Cím:In Vivo Assessments of Mesoblastic Nephroma (Ne/De) and Myelomonoblastic Leukaemia (My1/De) Tumour Development in Hypercholesterolemia Rat Models / Zita Képes, Alexandra Barkóczi, Judit P. Szabó, Ibolya Kálmán-Szabó, Viktória Arató, Ildikó Garai, Péter Árkosy, István Jószai, Ádám Deák, István Kertész, István Hajdu, György Trencsényi
Dátum:2022
ISSN:1422-0067
Megjegyzések:Given the rising prevalence of lipid metabolic disorders and malignant diseases, we aimed to establish an in vivo hypercholesterinaemic tumour-bearing rat model for the induction and assessment of these conditions. A normal standard CRLT/N, 2 (baseline),- or 4 (2 + 2, pretreated)-week-long butter and cholesterol rich (BCR) diet was applied to mesoblastic nephroma (Ne/De) and myelomonoblastic leukaemia (My1/De) tumour-bearing and healthy control Long-Evans and Fischer 344 rats. The beginning of chow administration started in parallel with tumour induction and the 2 weeks of pre-transplantation in the baseline and pretreated groups, respectively. Fourteen days post-inoculation, the measurement of lipid parameters and [F-18]F-FDG PET/MRI examinations was executed. The comparable lipid status of baseline healthy and tumorous rats proves that regardless of tumour presence, BCR-based hypercholesterolemia was achieved. A higher tumour mass among pretreated tumorous animals was found when compared to the control groups (p < 0.05, p < 0.01). Further, a visually greater [F-18]F-FDG accumulation was observed in pretreated BCR tumorous animals; however, the quantitative data (SUVmean: 9.86 +/- 0.98, 9.68 +/- 1.24; SUVmax: 19.63 +/- 1.20; 17.56 +/- 3.21 for Ne/De and My1/De, respectively) were not statistically significantly different from those of the CRLT/N tumorous rats (SUVmean: 8.40 +/- 1.42, 7.22 +/- 1.06 and SUVmax: 15.99 +/- 2.22, 12.46 +/- 1.96 for control Ne/De and My1/De, respectively). Our model seems to be appropriate for simultaneously investigating hypercholesterolemia and cancer in the same rat.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
butter and cholesterol-rich (BCR) diet
[18F]F-FDG PET/MRI
hypercholesterolemia
lipids
myelomonoblastic leukaemia (My1/De)
mesoblastic nephroma (Ne/De)
standardised uptake value (SUV)
Megjelenés:International Journal Of Molecular Sciences. - 23 : 21 (2022), p. 1-16. -
További szerzők:Barkóczi Alexandra Péli-Szabó Judit (1977-) (vegyész) Kálmán-Szabó Ibolya (1980-) (molekuláris biológus) Arató Viktória Zsófia (1989-) (gyógyszerész) Garai Ildikó (1966-) (radiológus) Árkosy Péter (1962-) (általános sebész, mellkassebész) Jószai István (1978-) (vegyész) Deák Ádám (1974-) (állatorvos) Kertész István (1966-) (vegyész) Hajdu István (1981-) (vegyész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus)
Pályázati támogatás:EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
K119552
NKFIH
TKP2020-NKA-04
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM117633
035-os BibID:(cikkazonosító)664 (WoS)001141423100001 (Scopus)85182205296
Első szerző:Trencsényi György (biológus, biokémikus, molekuláris biológus)
Cím:Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results / György Trencsényi, Csaba Csikos, Zita Képes
Dátum:2024
ISSN:1422-0067
Megjegyzések:Targeted alpha-particle therapy using radionuclides with alpha emission is a rapidly developing area in modern cancer treatment. To selectively deliver alpha-emitting isotopes to tumors, targeting vectors, including monoclonal antibodies, peptides, small molecule inhibitors, or other biomolecules, are attached to them, which ensures specific binding to tumor-related antigens and cell surface receptors. Although earlier studies have already demonstrated the anti-tumor potential of alpha-emitting radium (Ra) isotopes-Radium-223 and Radium-224 (Ra-223/224)-in the treatment of skeletal metastases, their inability to complex with target-specific moieties hindered application beyond bone targeting. To exploit the therapeutic gains of Ra across a wider spectrum of cancers, nanoparticles have recently been embraced as carriers to ensure the linkage of Ra-223/224 to target-affine vectors. Exemplified by prior findings, Ra was successfully bound to several nano/microparticles, including lanthanum phosphate, nanozeolites, barium sulfate, hydroxyapatite, calcium carbonate, gypsum, celestine, or liposomes. Despite the lengthened tumor retention and the related improvement in the radiotherapeutic effect of Ra-223/224 coupled to nanoparticles, the in vivo assessment of the radiolabeled nanoprobes is a prerequisite prior to clinical usage. For this purpose, experimental xenotransplant models of different cancers provide a well-suited scenario. Herein, we summarize the latest achievements with Ra-223/224-doped nanoparticles and related advances in targeted alpha radiotherapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
nanoparticles
preclinical
Radium-223/224 (223/224Ra)
targeted alpha-particle therapy
xenotransplants
Megjelenés:International Journal Of Molecular Sciences. - 25 : 1 (2024), p. 1-30. -
További szerzők:Csíkos Csaba Képes Zita (1991-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM113959
035-os BibID:(cikkazonosító)12675 (WoS)001056046300001 (Scopus)85168748804
Első szerző:Trencsényi György (biológus, biokémikus, molekuláris biológus)
Cím:NGR-Based Radiopharmaceuticals for Angiogenesis Imaging : a Preclinical Review / György Trencsényi, Kata Nóra Enyedi, Gábor Mező, Gábor Halmos, Zita Képes
Dátum:2023
ISSN:1422-0067
Megjegyzések:Angiogenesis plays a crucial role in tumour progression and metastatic spread; therefore, the development of specific vectors targeting angiogenesis has attracted the attention of several researchers. Since angiogenesis-associated aminopeptidase N (APN/CD13) is highly expressed on the surface of activated endothelial cells of new blood vessels and a wide range of tumour cells, it holds great promise for imaging and therapy in the field of cancer medicine. The selective binding capability of asparagine-glycine-arginine (NGR) motif containing molecules to APN/CD13 makes radiolabelled NGR peptides promising radiopharmaceuticals for the non-invasive, real-time imaging of APN/CD13 overexpressing malignancies at the molecular level. Preclinical small animal model systems are major keystones for the evaluation of the in vivo imaging behaviour of radiolabelled NGR derivatives. Based on existing literature data, several positron emission tomography (PET) and single-photon emission computed tomography (SPECT) radioisotopes have been applied so far for the labelling of tumour vasculature homing NGR sequences such as Gallium-68 (68Ga), Copper-64 (64Cu), Technetium-99m (99mTc), Lutetium-177 (177Lu), Rhenium-188 (188Re), or Bismuth-213 (213Bi). Herein, a comprehensive overview is provided of the recent preclinical experiences with radiolabelled imaging probes targeting angiogenesis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
aminopeptidase N (APN/CD13)
angiogenesis
NGR (asparagine-glycine-arginine)
preclinical
radioisotope
Megjelenés:International Journal Of Molecular Sciences. - 24 : 16 (2023), p. 1-34. -
További szerzők:Enyedi Kata Nóra (1987-) (vegyész) Mező Gábor (1959-) (vegyész) Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus) Képes Zita (1991-) (orvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
Thematic Excellence Programme TKP2021-EGA-20 (Biotechnology) of the Ministry for Innovation and Technology in Hungary
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM110785
035-os BibID:(cikkazonosító)7400 (Scopus)85156242117 (WoS)000977626300001
Első szerző:Trencsényi György (biológus, biokémikus, molekuláris biológus)
Cím:Scandium-44 : Diagnostic Feasibility in Tumor-Related Angiogenesis / Trencsényi György, Képes Zita
Dátum:2023
ISSN:1422-0067
Megjegyzések:Angiogenesis-related cell-surface molecules, including integrins, aminopeptidase N, vascular endothelial growth factor, and gastrin-releasing peptide receptor (GRPR), play a crucial role in tumour formation. Radiolabelled imaging probes targeting angiogenic biomarkers serve as valuable vectors in tumour identification. Nowadays, there is a growing interest in novel radionuclides other than gallium-68 (68Ga) or copper-64 (64Cu) to establish selective radiotracers for the imaging of tumour-associated neo-angiogenesis. Given its ideal decay characteristics (E?+average: 632 KeV) and a half-life (T1/2 = 3.97 h) that is well matched to the pharmacokinetic profile of small molecules targeting angiogenesis, scandium-44 (44Sc) has gained meaningful attention as a promising radiometal for positron emission tomography (PET) imaging. More recently, intensive research has been centered around the investigation of 44Sc-labelled angiogenesis-directed radiopharmaceuticals. Previous studies dealt with the evaluation of 44Sc-appended avb3 integrin?affine Arg-Gly-Asp (RGD) tripeptides, GRPR-selective aminobenzoyl?bombesin analogue (AMBA), and hypoxia-associated nitroimidazole derivatives in the identification of various cancers using experimental tumour models. Given the tumour-related hypoxia- and angiogenesis-targeting capability of these PET probes, 44Sc seems to be a strong competitor of the currently used positron emitters in radiotracer development. In this review, we summarize the preliminary preclinical achievements with 44Sc-labelled angiogenesis-specific molecular probes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
aminobenzoyl-bombesin analogue (AMBA
aminopeptidase N (APN/CD13)
angiogenesis
carcinogenesis
gastrin-releasing peptide receptor (GRPR)
integrin
nitroimidazole
positron emission tomography (PET)
Arg-Gly-Asp (RGD)
scandium-44 (44Sc)
Megjelenés:International Journal Of Molecular Sciences. - 24 : 8 (2023), p. 1-23. -
További szerzők:Képes Zita (1991-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1